162 related articles for article (PubMed ID: 19681684)
1. Response of malignant scalp dermatofibrosarcoma to presurgical targeted growth factor inhibition.
Mattox AK; Mehta AI; Grossi PM; Cummings TJ; Adamson DC
J Neurosurg; 2010 May; 112(5):965-77. PubMed ID: 19681684
[TBL] [Abstract][Full Text] [Related]
2. Dermatofibrosarcoma protuberans: recent clinical progress.
McArthur G
Ann Surg Oncol; 2007 Oct; 14(10):2876-86. PubMed ID: 17647063
[TBL] [Abstract][Full Text] [Related]
3. [Dermatofibrosarcoma protuberans].
Sanmartín O; Llombart B; López-Guerrero JA; Serra C; Requena C; Guillén C
Actas Dermosifiliogr; 2007 Mar; 98(2):77-87. PubMed ID: 17397592
[TBL] [Abstract][Full Text] [Related]
4. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
[TBL] [Abstract][Full Text] [Related]
5. Molecularly targeted treatment for dermatofibrosarcoma protuberans.
McArthur G
Semin Oncol; 2004 Apr; 31(2 Suppl 6):30-6. PubMed ID: 15176002
[TBL] [Abstract][Full Text] [Related]
6. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report.
Lemm D; Muegge LO; Hoeffken K; Aklan T; Mentzel T; Thorwarth M; Schultze-Mosgau S
Oral Maxillofac Surg; 2008 Dec; 12(4):209-13. PubMed ID: 18751744
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection.
Rutkowski P; Dębiec-Rychter M; Nowecki Z; Michej W; Symonides M; Ptaszynski K; Ruka W
J Eur Acad Dermatol Venereol; 2011 Mar; 25(3):264-70. PubMed ID: 20569296
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
[TBL] [Abstract][Full Text] [Related]
9. [Molecular approach in the treatment of dermatofibrosarcoma protuberans].
Fattoruso SI; Visca P; Lopez M
Clin Ter; 2008; 159(5):361-7. PubMed ID: 18998038
[TBL] [Abstract][Full Text] [Related]
10. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
[TBL] [Abstract][Full Text] [Related]
11. Current treatment options in dermatofibrosarcoma protuberans.
Lemm D; Mügge LO; Mentzel T; Höffken K
J Cancer Res Clin Oncol; 2009 May; 135(5):653-65. PubMed ID: 19205737
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP).
Gooskens SL; Oranje AP; van Adrichem LN; de Waard-van der Spek FB; den Hollander JC; van de Ven CP; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2010 Aug; 55(2):369-73. PubMed ID: 20582941
[TBL] [Abstract][Full Text] [Related]
13. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.
Wang C; Luo Z; Chen J; Zheng B; Zhang R; Chen Y; Shi Y
Medicine (Baltimore); 2015 May; 94(17):e773. PubMed ID: 25929918
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.
Han A; Chen EH; Niedt G; Sherman W; Ratner D
Arch Dermatol; 2009 Jul; 145(7):792-6. PubMed ID: 19620561
[TBL] [Abstract][Full Text] [Related]
15. Dermatofibrosarcoma protuberans: is mohs surgery truly superior? And the success of tyrosine kinase inhibitors.
Kallini JR; Khachemoune A
J Drugs Dermatol; 2014 Dec; 13(12):1474-7. PubMed ID: 25607791
[TBL] [Abstract][Full Text] [Related]
16. [From cytogenetics to cytogenomics of dermatofibrosarcoma protuberans family of tumors].
Bianchini L; Maire G; Pedeutour F;
Bull Cancer; 2007 Feb; 94(2):179-89. PubMed ID: 17337387
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients.
Kérob D; Porcher R; Vérola O; Dalle S; Maubec E; Aubin F; D'Incan M; Bodokh I; Boulinguez S; Madelaine-Chambrin I; Mathieu-Boue A; Servant JM; de Kerviler E; Janin A; Calvo F; Pedeutour F; Lebbe C
Clin Cancer Res; 2010 Jun; 16(12):3288-95. PubMed ID: 20439456
[TBL] [Abstract][Full Text] [Related]
18. Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses.
Johnson-Jahangir H; Sherman W; Ratner D
J Natl Compr Canc Netw; 2010 Aug; 8(8):881-5. PubMed ID: 20870634
[TBL] [Abstract][Full Text] [Related]
19. Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications.
Llombart B; Sanmartín O; López-Guerrero JA; Monteagudo C; Serra C; Requena C; Poveda A; Vistós JL; Almenar S; Llombart-Bosch A; Guillén C
Histopathology; 2009 Jun; 54(7):860-72. PubMed ID: 19635106
[TBL] [Abstract][Full Text] [Related]
20. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.
Stacchiotti S; Pedeutour F; Negri T; Conca E; Marrari A; Palassini E; Collini P; Keslair F; Morosi C; Gronchi A; Pilotti S; Casali PG
Int J Cancer; 2011 Oct; 129(7):1761-72. PubMed ID: 21128251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]